GRTX (Galera Therapeutics Inc.) קפיטליזציה חשבונאית

The safety of Galera Therapeutics (GRTX) clinical programs relies on strict control over the transportation of medical cargo. The business is currently closing its operating cycle due to the failure of its primary drug, fixing capital at -0.14. This daily price chart clearly demonstrates these challenges. Previously, Galera Therapeutics (GRTX) sought to expand the use of small molecules for radiation protection, planning to capture market share.

Book value capitalization reflects the current value of the issuer's net assets, stripping equity of reporting lags to assess the actual asset base. By analyzing the book capitalization of Galera Therapeutics (GRTX), an investor can identify the residual liquidity of Galera Therapeutics, which, amid the termination of R&D programs and regulatory failures, serves as an indicator of distributable cash assets prior to the final closure of the business.